This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baruch, D. I.
Right arrow Articles by Miller, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baruch, D. I.
Right arrow Articles by Miller, L. H.

 Previous Article  |  Next Article 

Infection and Immunity, August 2003, p. 4536-4543, Vol. 71, No. 8
0019-9567/03/$08.00+0     DOI: 10.1128/IAI.71.8.4536-4543.2003

DNA Immunization with the Cysteine-Rich Interdomain Region 1 of the Plasmodium falciparum Variant Antigen Elicits Limited Cross-Reactive Antibody Responses

Dror I. Baruch,* Benoit Gamain, and Louis H. Miller

Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892

Received 28 February 2003/ Returned for modification 12 April 2003/ Accepted 2 May 2003

The variant surface antigens of Plasmodium falciparum are an important component of naturally acquired immunity and an important vaccine target. However, these proteins appear to elicit primarily variant-specific antibodies. We tested if naked DNA immunization can elicit more cross-reactive antibody responses and allow simultaneous immunization with several variant constructs. Mice immunized with plasmid DNA expressing variant cysteine-rich interdomain region 1 (CIDR1) domains of the P. falciparum erythrocyte membrane protein 1 (PfEMP1) developed antibodies that were reactive to the corresponding PfEMP1s as measured by an enzyme-linked immunosorbent assay, flow cytometry, and agglutination of parasitized erythrocytes (PEs). We observed some cross-reactive immune responses; for example, sera from mice immunized with one domain agglutinated PEs of various lines and recognized heterologous domains expressed on the surface of Chinese hamster ovary (CHO) cells. We found no significant antigenic competition when animals were immunized with a mixture of plasmids or immunized sequentially with individual constructs. Moreover, mixed or sequential immunizations resulted in greater cross-reactive agglutination responses than immunization with a single domain. Recombinant protein (Sc y179) immunization after priming with DNA (prime-boost regimen) increased antibody titers to the homologous domain substantially but seemed to diminish the cross-reactive responses somewhat. The titer of agglutinating antibodies was previously shown to correlate with protection. Surprisingly, the agglutination titers of sera from DNA immunization were high, similar to those of pooled human hyperimmune sera. These sera also appeared to give limited low-titer variant transcending agglutination. Thus, DNA immunization appears to be a very useful tool for developing variant antigen vaccines.


* Corresponding author. Mailing address: Laboratory of Malaria and Vector Research, NIAID, NIH, Bldg. 4, Room B1-37, 4 Center Drive MSC 0425, Bethesda, MD 20892-0425. Phone: (301) 451-4945. Fax: (301) 402-0079. E-mail: dbaruch{at}niaid.nih.gov.

Editor: W. A. Petri, Jr.


Infection and Immunity, August 2003, p. 4536-4543, Vol. 71, No. 8
0019-9567/03/$08.00+0     DOI: 10.1128/IAI.71.8.4536-4543.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Avril, M., Kulasekara, B. R., Gose, S. O., Rowe, C., Dahlback, M., Duffy, P. E., Fried, M., Salanti, A., Misher, L., Narum, D. L., Smith, J. D. (2008). Evidence for Globally Shared, Cross-Reacting Polymorphic Epitopes in the Pregnancy-Associated Malaria Vaccine Candidate VAR2CSA. Infect. Immun. 76: 1791-1800 [Abstract] [Full Text]  
  • Moll, K., Pettersson, F., Vogt, A. M., Jonsson, C., Rasti, N., Ahuja, S., Spangberg, M., Mercereau-Puijalon, O., Arnot, D. E., Wahlgren, M., Chen, Q. (2007). Generation of Cross-Protective Antibodies against Plasmodium falciparum Sequestration by Immunization with an Erythrocyte Membrane Protein 1-Duffy Binding-Like 1{alpha} Domain. Infect. Immun. 75: 211-219 [Abstract] [Full Text]  
  • Joergensen, L., Turner, L., Magistrado, P., Dahlback, M. A., Vestergaard, L. S., Lusingu, J. P., Lemnge, M., Salanti, A., Theander, T. G., Jensen, A. T. R. (2006). Limited Cross-Reactivity among Domains of the Plasmodium falciparum Clone 3D7 Erythrocyte Membrane Protein 1 Family. Infect. Immun. 74: 6778-6784 [Abstract] [Full Text]  
  • Ndungu, F. M., Sanni, L., Urban, B., Stephens, R., Newbold, C. I., Marsh, K., Langhorne, J. (2006). CD4 T Cells from Malaria-Nonexposed Individuals Respond to the CD36-Binding Domain of Plasmodium falciparum Erythrocyte Membrane Protein-1 via an MHC Class II-TCR-Independent Pathway. J. Immunol. 176: 5504-5512 [Abstract] [Full Text]  
  • ABDEL-LATIF, M. S., CABRERA, G., KOHLER, C., KREMSNER, P. G., LUTY, A. J. F. (2004). ANTIBODIES TO RIFIN: A COMPONENT OF NATURALLY ACQUIRED RESPONSES TO PLASMODIUM FALCIPARUM VARIANT SURFACE ANTIGENS ON INFECTED ERYTHROCYTES. Am J Trop Med Hyg 71: 179-186 [Abstract] [Full Text]  
  • Mayer, D. C. G., Mu, J.-B., Kaneko, O., Duan, J., Su, X.-z., Miller, L. H. (2004). Polymorphism in the Plasmodium falciparum erythrocyte-binding ligand JESEBL/EBA-181 alters its receptor specificity. Proc. Natl. Acad. Sci. USA 101: 2518-2523 [Abstract] [Full Text]  
  • Gratepanche, S., Gamain, B., Smith, J. D., Robinson, B. A., Saul, A., Miller, L. H. (2003). Induction of crossreactive antibodies against the Plasmodium falciparum variant protein. Proc. Natl. Acad. Sci. USA 100: 13007-13012 [Abstract] [Full Text]